Clinical trialEarly Phase 1Withdrawn
Phase I, FIH, MTD for MPT0B640, Multi-centre, Open-label, Subject With Locally Advanced or Metastatic Solid Malignancies
Phase l, First in Human, Multi-centre, Open-label, Clinical Trial of MPT0B640 in Subject With Locally Advanced or Metastatic Solid Malignancies
- Outcome
- Stopped earlyStudy held. (Other)
- Phase
- Early Phase 1
- Status
- Withdrawn
- Study type
- Interventional
- Planned start
- December 2025
- Planned end
- November 2027
- Enrollment
- 0 participants
- Sites
- 0
- Primary outcomes
- MTD of the dose of MPT0B640
- Sponsor type
- Industry
- Results posted
- No
- Last update
- 6 March 2024
These fields come from the trial’s registry entry. A summary of its population, design, endpoints and results, each tied to a quote, has not been written for this trial yet.
Ask this document
Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.
Try
Source text
Brief summary public domain (ClinicalTrials.gov)
Phase l, First in Human, Multi-centre, Open-label, Clinical Trial of MPT0B640 in Subject with Locally Advanced or Metastatic Solid Malignancies Phase I. Advanced or metastatic solid malignancy First in Human. HSP90 inhibitor Multi-center clinical trials. Open label. To determine the maximum tolerated dose (MTD) or maximum feasible dose (MFD) of MPT0B640
Detailed description public domain (ClinicalTrials.gov)
Classical 3+3 design to determine the maximum tolerated dose (MTD) or maximum feasible dose (MFD) of MPT0B640 . Up to 9 times of administration, Oral suspension, once every 3rd day.